No stock is ever a sure thing, but that doesn’t mean you can’t get asymptotically close to one. Following the announcement by VBI Vaccines, Inc.
Keep Reading →
November 14 - News, Stock Analysis
While the wider biotech space was enjoying something of a unexpected return to positive sentiment on Wednesday and Thursday, buoyed by the lifting of the potential investigations...
Keep Reading →
November 11 - News, Stock Analysis
AstraZeneca PLC (ADR) (NYSE:AZN) will no longer seek early regulatory review of its drug candidate durvalumab in patients with head and neck cancers.
Keep Reading →
November 11 - Earnings Report, News, Stock Analysis
Polish biotech company Mabion SA (WSE:MAB) just announced the signing of a supply and commercialization agreement with Mylan NV (NASDAQ:MYL), by way of its subsidiary Mylan Ireland...
Keep Reading →
November 11 - News, Stock Analysis
We’re closing in on the end of the week, and it’s time to take a look at which of the companies in the biotech space have moved the most, and what’s driving the action behind...
Keep Reading →
November 11 - Market Movers, News, Stock Analysis
Array Biopharma Inc (NASDAQ:ARRY) and its partner Pierre Fabre took the opportunity at the Society for Melanoma Research Annual Congress to share results for its COLUMBUS Phase...
Keep Reading →
November 10 - News, Stock Analysis
The Humulin R U-500 insulin is prescribed to patients who need a higher dose of insulin on a daily basis.
Keep Reading →
November 10 - News, Stock Analysis
Bristol-Myers Squibb Co (NYSE:BMY) and Infinity Pharmaceuticals Inc.
Keep Reading →
November 10 - News, Stock Analysis
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) just put out its third quarter 2016 earnings, and the company took a bit of a dive on the numbers.
Keep Reading →
November 9 - News, Stock Analysis
Pfizer Inc. (NYSE:PFE) has recently revealed that it is closing two manufacturing plants in Britain.
Keep Reading →
November 9 - News
The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) has decided not to embark on the review of the 166 formulation patent of AbbVie Inc (NYSE:ABBV) ...
Keep Reading →
November 9 - News
While wider markets turn there focus to the US elections, the biotech space is alive and well, and after a tough end to last week, a number of companies have enjoyed gains throughout...
Keep Reading →
November 8 - Market Movers, News
Horizon Pharma PLC (NASDAQ:HZNP) is up circa 15% on its Q3 2016 earnings report, and the company looks set to continue picking up strength even against a backdrop of politically...
Keep Reading →
November 8 - News, Stock Analysis
Eylea has been one of the main drivers of growth for Regeneron over the past couple of years.
Keep Reading →
November 8 - News, Stock Analysis
The US Food and Drug Administration (FDA) has recently cleared the Propeller platform of Propeller Health for use with GlaxoSmithKline Plc (ADR) (NYSE:GSK)'s Ellipta dry powder...
Keep Reading →
November 8 - News, Stock Analysis
Abbott Laboratories (NYSE:ABT) has sued Alere Inc (NYSE:ALR), a diagnostics company it agreed to acquire earlier this year, for breach of contract.
Keep Reading →
November 4 - News, Stock Analysis
A few weeks ago, we highlighted development stage biotechnology company Innocoll Holdings PLC (NASDAQ:INNL) as being one to watch as we headed into the middle of the fourth quarter...
Keep Reading →
November 4 - News, Stock Analysis
Another big day in the biotech sector? You bet.
Keep Reading →
November 3 - Market Movers, News
AveXis Inc (NASDAQ:AVXS) just announced that it has secured a favorable trial design for its ongoing investigation of its lead asset, AVXS-101, in its investigation into spinal...
Keep Reading →
November 3 - News, Stock Analysis
Sanofi SA (ADR) (NYSE:SNY) Pasteur seems to be making it big with its vaccines. In the third quarter the French drugmaker’s sales grew by 14% over last year.
Keep Reading →
November 3 - News, Stock Analysis
The entirety of the long investment game comes down to being able to accurately spot the undervalued. Undervaluation exists for many reasons.
Keep Reading →
November 3 - News, Stock Analysis
Canada’s Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is contemplating selling some of its assets the most notable one being it’s Salix gastrointestinal unit.
Keep Reading →
November 3 - News, Stock Analysis
On October 13, the FDA informed Egalet Corp (NASDAQ:EGLT) that it would not meet the Prescription Drug User Fee Act (PDUFA) date for its decision on Arymo ER.
Keep Reading →
November 3 - News, Stock Analysis
We’re now heading in to the home straight for the week, and there has been plenty to go at from an intraday perspective in the biotech space.
Keep Reading →
November 2 - News, Stock Analysis
Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)'s Ibrance.
Keep Reading →
November 2 - News
Palatin Technologies, Inc. (NYSEMKT:PTN) is soaring on data released from its lead female libido trial.
Keep Reading →
November 2 - News, Stock Analysis
Eli Lilly and Co (NYSE:LLY) has categorically stated to its regulators and investors that it is hanging onto a possible nod from the FDA for a new indication for Jardiance.
Keep Reading →
November 2 - News, Stock Analysis
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)'s lung cancer drug brigatinib has been accepted for review by the FDA.
Keep Reading →
November 2 - News, Stock Analysis
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) have moved closer to introducing their generic version of Johnson & Johnson...
Keep Reading →
November 1 - News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will have to wait for a court ruling over its IP protection for its lifelong multiple sclerosis therapy, Copaxone.
Keep Reading →
November 1 - News
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) just announced that it is carrying forward with a special protocol assessment (SPA) for its lead asset, Firdapse, for the treatment ...
Keep Reading →
November 1 - News, Stock Analysis
While biotechs big and small are busy slogging through a years-to-decades long clinical trial process and burning though hundreds of millions on the way, here’s a comforting...
Keep Reading →
November 1 - News, Stock Analysis
Novo Nordisk A/S (ADR) (NYSE:NVO) incoming President and CEO Lars Fruergaard Jørgensen is slated to start his leadership roles in the New Year.
Keep Reading →
November 1 - News
Cempra Inc (NASDAQ:CEMP) just announced that it may not meet its PDUFA for solithromycin, and the company has taken a big hit on the news.
Keep Reading →
October 31 - News, Stock Analysis
So we’re going to close out the week with a roundup of some of the companies that have moved the most over the last couple of sessions, and what’s driving the movement.
Keep Reading →
October 28 - Market Movers, News, Stock Analysis
ProQR Therapeutics NV (NASDAQ:PRQR) just put out data from its early stage cystic fibrosis (CF) study, and the numbers sent the company’s market capitalization on a nice upside...
Keep Reading →
October 27 - News, Stock Analysis
While the US Food and Drug Administration (FDA) has recently kicked out knockoff versions of Concerta, the attention deficit hyperactivity disorder (ADHD) drug from Johnson & ...
Keep Reading →
October 27 - News, Stock Analysis
AstraZeneca plc (ADR) (NYSE:AZN) has recently released encouraging data from SOLO-2, a phase 3 clinical trial evaluating the efficacy of Lynparza (olaparib) as a monotherapy for...
Keep Reading →
October 27 - News, Stock Analysis
A short term peak back in June aside, which saw the company rise through the $10 mark before giving back its gains and more, Innocoll Holdings PLC (NASDAQ:INNL) has traded essentially...
Keep Reading →
October 26 - News, Stock Analysis
It’s going to be a busy quarter for a few companies in the biotech space, with a number of catalysts slated for the next month or so.
Keep Reading →
October 26 - News, Stock Analysis
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has introduced a smaller capsule of its branded drug Vascepa. The new size is a half-gram (0.5-gram) capsule.
Keep Reading →
October 26 - News, Stock Analysis
GlaxoSmithKline plc (ADR) (NYSE:GSK) (GSK) has recently entered into a collaborative agreement with Fimbrion Therapeutics, Inc.
Keep Reading →
October 26 - News, Stock Analysis
The US Food and Drug Administration (FDA) has recently approved the anti-programmed-death-receptor-1 (anti-PD-1) therapy of Merck & Co., Inc.
Keep Reading →
October 26 - News, Stock Analysis
Yet again, it’s been a busy start to the week in biotech. A couple of companies have picked up early week gains, but more have suffered, and some considerably.
Keep Reading →
October 25 - News, Stock Analysis
Inovio Pharmaceuticals Inc (NASDAQ:INO) took a beating on Monday, on the news that the company has picked up a clinical hold for its lead cervical cancer asset, and that as a...
Keep Reading →
October 25 - News, Stock Analysis
At the end of last week, we highlighted Alkermes Plc (NASDAQ:ALKS) as being one of the biggest movers in the biotechnology space for the month.
Keep Reading →
October 24 - News, Stock Analysis
The fourth quarter of this year is set to be a big one in the biotech space, with a number of key development slated across October, November and December.
Keep Reading →
October 20 - News, Stock Analysis
BioMarin Pharmaceutical Inc.
Keep Reading →
October 20 - News, Stock Analysis
Pier 1 Imports Inc (NYSE:PIR) and one of its largest institutional investors could be headed for a serious clash over how the company should be run.
Keep Reading →
October 20 - Activism, Hedge Funds, News
It’s been another busy start to the week in biotech, with a number of companies moving double digit percentage points on various fundamental releases.
Keep Reading →
October 20 - Market Movers, News
